DK3608330T3 - Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater - Google Patents

Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater Download PDF

Info

Publication number
DK3608330T3
DK3608330T3 DK19167964.6T DK19167964T DK3608330T3 DK 3608330 T3 DK3608330 T3 DK 3608330T3 DK 19167964 T DK19167964 T DK 19167964T DK 3608330 T3 DK3608330 T3 DK 3608330T3
Authority
DK
Denmark
Prior art keywords
oligosaccharide
preparation
protein conjugates
synthetic intermediates
intermediates
Prior art date
Application number
DK19167964.6T
Other languages
English (en)
Inventor
Clark Q Pan
Xiaoyang Zheng
Robert J Miller
Joseph P Kutzko
Yunxiang Zhu
Duncan E Patterson
Andreas Peer
Paul A Konowicz
Luis Z Avila
James E Stefano
Michael R Reardon
John Harrahy
Qun Zhou
Lauren Young
Patrick Finn
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK3608330T3 publication Critical patent/DK3608330T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK19167964.6T 2008-12-16 2009-12-11 Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater DK3608330T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12285108P 2008-12-16 2008-12-16
EP14194176.5A EP2889043B1 (en) 2008-12-16 2009-12-11 Synthetic intermediates for preparing oligosaccharide-protein conjugates

Publications (1)

Publication Number Publication Date
DK3608330T3 true DK3608330T3 (da) 2023-02-06

Family

ID=42138937

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12160009.2T DK2465542T3 (da) 2008-12-16 2009-12-11 Oligosaccharid-protein-konjugater
DK19167964.6T DK3608330T3 (da) 2008-12-16 2009-12-11 Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater
DK14194176.5T DK2889043T3 (da) 2008-12-16 2009-12-11 Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12160009.2T DK2465542T3 (da) 2008-12-16 2009-12-11 Oligosaccharid-protein-konjugater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14194176.5T DK2889043T3 (da) 2008-12-16 2009-12-11 Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater

Country Status (21)

Country Link
US (5) US8835614B2 (da)
EP (5) EP2376123A2 (da)
JP (6) JP5658167B2 (da)
CN (5) CN103432566A (da)
BR (2) BRPI0923047B8 (da)
CA (2) CA3040973A1 (da)
CY (1) CY1121860T1 (da)
DK (3) DK2465542T3 (da)
ES (3) ES2937017T3 (da)
HK (2) HK1171697A1 (da)
HR (2) HRP20150340T1 (da)
HU (2) HUE060974T2 (da)
IL (5) IL213595B (da)
LT (1) LT2889043T (da)
MX (3) MX364498B (da)
PL (2) PL2889043T3 (da)
PT (2) PT2465542E (da)
SI (2) SI2889043T1 (da)
SM (1) SMT201500082B (da)
TR (1) TR201909909T4 (da)
WO (1) WO2010075010A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
PT2457920T (pt) * 2007-01-18 2018-01-23 Genzyme Corp Oligossacáridos compreendendo um grupo aminooxi e conjugados dos mesmos
CN103432566A (zh) * 2008-12-16 2013-12-11 建新公司 寡糖-蛋白缀合物
LT3482767T (lt) 2009-08-28 2022-01-10 Icahn School Of Medicine At Mount Sinai Didinamos dozės fermentų pakaitinė terapija, skirta rūgštinės sfingomielinazės nepakankamumui gydyti
WO2012145644A1 (en) 2011-04-22 2012-10-26 Genzyme Corporation Modified acid alpha glucosidase with accelerated processing
US20140377244A1 (en) * 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
WO2013176239A1 (ja) * 2012-05-24 2013-11-28 国立大学法人 東京大学 酸化オリゴ糖で架橋したゲル材料
PL3201320T3 (pl) * 2014-09-30 2024-03-18 Amicus Therapeutics, Inc. Bardzo silnie działająca kwasowa alfa-glukozydaza ze zwiększoną zawartością węglowodanów
CN107429257B (zh) 2015-03-17 2022-02-15 艾丽法有限责任公司 糖基化溶酶体蛋白、生产方法和用途
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017117407A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
PE20190127A1 (es) 2016-03-30 2019-01-17 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
JP6996676B2 (ja) * 2016-03-30 2022-02-04 国立研究開発法人農業・食品産業技術総合研究機構 マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法
EP3439704A1 (en) * 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
CN106366163A (zh) * 2016-10-31 2017-02-01 中国人民解放军第二军医大学 一种β‑1,2‑D‑寡聚甘露糖肽‑蛋白缀合物及其制备方法和应用
CN106432371A (zh) * 2016-10-31 2017-02-22 中国人民解放军第二军医大学 β‑1,2‑D‑寡聚甘露糖蛋白缀合物及其制备方法和应用
CA3105823C (en) * 2018-07-09 2023-07-25 Merck Sharp & Dohme Corp. Enzymatic synthesis of 4'-ethynyl nucleoside analogs
US20210244803A1 (en) * 2020-02-08 2021-08-12 Genzyme Corporation Compositions and methods for treating pompe disease
MX2022016019A (es) 2020-06-14 2023-04-10 Genzyme Corp Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio.

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701521A (en) 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4749570A (en) 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS5936691A (ja) * 1982-08-24 1984-02-28 Rikagaku Kenkyusho 新規オリゴマンノシド及びその製造法
US5851991A (en) 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5206370A (en) 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
IL93432A (en) 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5212298A (en) 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5583042A (en) 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
US5312903A (en) * 1990-06-01 1994-05-17 E. I. Du Pont De Nemours And Company Lysine-glycosylated recombinant interleukin-2
US5677440A (en) 1990-07-16 1997-10-14 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5492821A (en) 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
ATE368472T1 (de) * 1991-12-20 2007-08-15 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
FR2721612B1 (fr) 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5910487A (en) 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5747471A (en) 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5811510A (en) 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CA2230758A1 (en) 1995-09-08 1997-03-13 Genzyme Corporation Improved aav vectors for gene therapy
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7141676B1 (en) 1996-02-08 2006-11-28 University Of Washington Water soluble multi-biotin-containing compounds
CA2249323A1 (en) * 1996-03-21 1997-09-25 Transcell Technologies, Inc. Solid phase lipoglycopeptide library, compositions and methods
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
AUPO190596A0 (en) 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
EP0935651B1 (en) 1996-09-13 2004-12-29 Transkaryotic Therapies, Inc. THERAPY FOR alpha-GALACTOSIDASE A DEFICIENCY
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
DK0959905T3 (da) 1997-01-21 2010-04-06 Sanofi Pasteur Polysaccharid-peptid-konjugater
US5925628A (en) 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
SE513149C2 (sv) 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
WO1999041399A1 (en) 1998-02-17 1999-08-19 Genzyme Corporation Methods for purified aav vector production
JP2002538758A (ja) 1998-02-17 2002-11-19 ジェンザイム・コーポレイション 偽アデノウイルスベクターの製造方法
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6538117B1 (en) 1999-08-10 2003-03-25 The Scripps Research Institute Programmable one-pot oligosaccharide synthesis
US6399575B1 (en) 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
WO2001007078A1 (en) 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
DE60034478T2 (de) 1999-11-16 2008-01-10 Genzyme Corp., Cambridge Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
IL151024A0 (en) 2000-02-15 2003-02-12 Genzyme Corp Conjugates of a biopolymer and a therapeutic agent
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
AU2001236713A1 (en) 2000-02-17 2001-08-27 Genzyme Corporation Methods for treatment of lysosomal storage diseases
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040067527A1 (en) 2000-07-26 2004-04-08 Sara Lavi Intracellular delivery system for protein phosphatases and other polypeptides
AU8653901A (en) 2000-08-18 2002-03-04 Massachusetts Inst Technology Apparatus and methods for the automated synthesis of oligosaccharides
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
AU2001260526A1 (en) 2001-05-07 2001-12-03 Supratek Pharma, Inc. A ligand for enhancing oral and cns delivery of biological agents
ES2399323T3 (es) 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
ES2606840T3 (es) 2001-10-10 2017-03-28 Ratiopharm Gmbh Remodelación y glicoconjugación de factor estimulante de colonias de granulocitos (G-CSF)
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
CA2468295C (en) * 2001-11-28 2010-08-03 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
EP1585817B1 (en) 2002-02-20 2009-09-02 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
SI2857036T1 (sl) 2003-01-31 2017-05-31 Mount Sinai School Of Medicine Of New York University Kombinirana terapija za zdravljenje motenj pomanjkanja proteinov
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
RU2327703C2 (ru) 2003-08-12 2008-06-27 Лайпоксен Текнолоджиз Лимитед Производные полисиаловой кислоты
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
AU2005209303A1 (en) 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
JP2007523648A (ja) 2004-02-06 2007-08-23 バイオマリン ファーマシューティカル インコーポレイテッド 高リン酸化リソソーム酵素製剤及びそれらの使用
PL1740204T3 (pl) 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8716033B2 (en) * 2006-02-10 2014-05-06 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
PT2457920T (pt) 2007-01-18 2018-01-23 Genzyme Corp Oligossacáridos compreendendo um grupo aminooxi e conjugados dos mesmos
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
CN103432566A (zh) 2008-12-16 2013-12-11 建新公司 寡糖-蛋白缀合物

Also Published As

Publication number Publication date
IL237932A0 (en) 2015-05-31
HUE044381T2 (hu) 2019-10-28
WO2010075010A3 (en) 2011-01-06
IL237932B (en) 2019-12-31
MX364498B (es) 2019-04-29
EP4212541A1 (en) 2023-07-19
IL270930B (en) 2021-07-29
EP2889043A3 (en) 2015-07-22
EP3608330A3 (en) 2020-05-13
DK2465542T3 (da) 2015-04-27
JP2019112444A (ja) 2019-07-11
CA3040973A1 (en) 2010-07-01
US11279725B2 (en) 2022-03-22
EP2465542A1 (en) 2012-06-20
IL237933A0 (en) 2015-05-31
EP2889043B1 (en) 2019-04-10
DK2889043T3 (da) 2019-07-15
WO2010075010A2 (en) 2010-07-01
JP2014139204A (ja) 2014-07-31
JP5658167B2 (ja) 2015-01-21
IL213595A0 (en) 2011-07-31
SI2889043T1 (sl) 2019-08-30
HRP20150340T1 (hr) 2015-07-31
HK1171697A1 (en) 2013-04-05
BRPI0923047A2 (pt) 2015-12-08
LT2889043T (lt) 2019-07-10
EP2465542B1 (en) 2015-01-21
JP2021169467A (ja) 2021-10-28
US10464962B2 (en) 2019-11-05
US20110300120A1 (en) 2011-12-08
CN102369023A (zh) 2012-03-07
SMT201500082B (it) 2015-07-09
PT2465542E (pt) 2015-04-16
CN103432566A (zh) 2013-12-11
BRPI0923047B8 (pt) 2021-05-25
PL2889043T3 (pl) 2019-09-30
SI2465542T1 (sl) 2015-05-29
CA2747230A1 (en) 2010-07-01
HK1210413A1 (en) 2016-04-22
EP3608330B1 (en) 2022-11-09
BR122020010601B8 (pt) 2021-07-27
JP2023164869A (ja) 2023-11-14
MX2019004905A (es) 2020-11-12
IL284184B2 (en) 2023-06-01
HUE060974T2 (hu) 2023-04-28
IL284184A (en) 2021-07-29
US20200216485A1 (en) 2020-07-09
MX2011006347A (es) 2011-09-06
EP2376123A2 (en) 2011-10-19
IL270930A (en) 2020-01-30
BRPI0923047B1 (pt) 2020-11-24
ES2937017T3 (es) 2023-03-23
PT2889043T (pt) 2019-07-16
US20220242899A1 (en) 2022-08-04
JP2017008098A (ja) 2017-01-12
TR201909909T4 (tr) 2019-07-22
CN112618724A (zh) 2021-04-09
US8835614B2 (en) 2014-09-16
US20150175643A1 (en) 2015-06-25
BR122020010601B1 (pt) 2021-02-23
CA2747230C (en) 2019-06-11
HRP20191102T1 (hr) 2019-09-20
US20180002365A1 (en) 2018-01-04
IL213595B (en) 2018-02-28
EP2889043A2 (en) 2015-07-01
US9493498B2 (en) 2016-11-15
JP2012512313A (ja) 2012-05-31
JP6659503B2 (ja) 2020-03-04
CY1121860T1 (el) 2020-07-31
ES2534056T3 (es) 2015-04-17
EP3608330A2 (en) 2020-02-12
ES2735023T3 (es) 2019-12-13
CN105879047A (zh) 2016-08-24
PL2465542T3 (pl) 2015-06-30
CN112220930A (zh) 2021-01-15

Similar Documents

Publication Publication Date Title
DK3608330T3 (da) Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0807453A2 (pt) Preparação sólida
BRPI0907237A2 (pt) Anticorpo anti-cldn6
DK2231565T3 (da) Fremgangsmåder til fremstilling af clorerede carbonhydrider
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
DK2252395T3 (da) Afsvovlingsmaterialer
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0818079A2 (pt) composição de lipideo
BRPI0915047A2 (pt) Composição herbicida
DK2125048T3 (da) Præparat
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BRPI0909633A2 (pt) anticorpos anti-tyrp1
DE112010000691A5 (de) Chromatographievorrichtung
BRPI0912769A2 (pt) anticorpos anti-pirb
DK2382224T3 (da) Metalhydracid-materialer
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
DK2493860T3 (da) Fremgangsmåde til fremstilling af 4-sulfinylpyrazolderivater
BRPI0909461A2 (pt) Composto de enaminotiocarbonila substituídos
FI20080112A0 (fi) Seos
DK2462108T3 (da) Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider
BRPI0920833A2 (pt) preparação de benzonorborbenos